Pharmaceuticals
John H. Stewart
Beginning Q2 2017, Emblem will be launching cannabinoid-based medications in customary pharmaceutical dosage forms such as liquids, gel caps, oral sprays and
inhalers
Headed by John H. Stewart
• President & CEO of Purdue Pharma
(Canada 1991-2006, US 2006-2013)
• 30+ years experience in developing and commercializing pharmaceutical
products
• Launched 11 new products, including Biphentin, MS Contin, Zytram XL and
the $2B per year OxyContin
• Invested +$900,000 into Emblem
Facts
• The active components are extracted from cannabis plants and can be used in
liquid form (cannabis oil) or incorporated into other formulations
• LP’s can now monetize the entire cannabis
plant, not just the dried flower
• Patients are seeking more discreet
and easily managed dosage forms of
medical cannabis
• Physicians are looking for more
precise control of cannabinoid
dosages, and assurance of
consistency and stability
• The availability of pharmaceutical
formulations of cannabis will
significantly expand the medical
marijuana market
47